학술논문

Cytotoxicity of curcumin against [CD44.sup.[+ or -]] prostate cancer cells: Roles of miR-383 and miR-708
Original Research Article
Document Type
Periodical
Source
Avicenna Journal of Phytomedicine. July-August 2023, Vol. 13 Issue 4, p429, 13 p.
Subject
Iran
Language
English
Abstract
Introduction According to GLOBOCAN 2020, prostate cancer (PC) incidence is almost 1.3 million per year. In 2020, PC accounted for 359,000 deaths worldwide (Sung et al., 2021). A more and [...]
Objective: Cancer stem cells (CSCs) remaining in the tumor tissues after applying treatments may cause recurrence or metastasis of prostate cancer (PC). Curcumin has the promising potential to target CSCs. Here, we aim to evaluate the cytotoxic effects of curcumin on the expression of miR-383-5p and miR-708-5p and their target genes in [CD44.sup.+] CSCs and CD44- non-CSCs isolated from the PC3 prostate cancer cell line. Materials and Methods: We used MTT assay to determine the optimal cytotoxic dose of curcumin on [CD44.sup.[+ or -]] PC cells. Then, we assessed nuclear morphological changes using DAPi staining. We used Annexin V-FITC/PI to quantify apoptotic cell death. qRT-PCR was also used to detect miRNA and gene expression levels after curcumin treatment. Results: Curcumin significantly enhanced the apoptosis in both [CD44.sup.-] and [CD44.sup.+] PC cells in a dose-dependent manner (p < 0.05). The cytotoxicity of curcumin against [CD44.sup.-] cells ([IC.sub.50] 40.30[+ or -]2.32 [mu]M) was found to be greater than that against [CD44.sup.+] cells ([IC.sub.50] 83.31[+ or -]2.91 [mu]M). Also, curcumin promoted miR-383-5p and miR-708-5p overexpression while downregulating their target genes LDHA, PRDX3, and RAP1B, LSD1, respectively. Conclusion: Our findings indicate that curcumin, by promoting the expression of tumor suppressors, miR-383-5p and miR-708-5p, and inhibiting their target genes, induced its cytotoxicity against [CD44.sup.[+ or -]] PC cells. We trust that curcumin could be established as a promising adjuvant therapy to current PC treatment options following more research in clinical settings.